Pralsetinib
Lung Cancer Awareness Month: Potential new standard in NSCLC, immunotherapy timing matters
Lung Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors of the disease.
Company warns about risk for severe infections with drug approved for lung, thyroid cancers
Data from a phase 3 trial designed to compare pralsetinib with standard therapy for certain patients with advanced lung cancer revealed a risk for severe — and potentially fatal — infections with the drug, according to its manufacturer.
FDA grants regular approval to Gavreto for lung cancer subset
The FDA granted regular approval to pralsetinib for treatment of certain patients with non-small cell lung cancer.
VIDEO: New data on medullary thyroid cancer at American Thyroid Association Annual Meeting
In this video, Maria E. Cabanillas, MD, an oncologic endocrinologist at The University of Texas MD Anderson Cancer Center, discussed an update to the ARROW study.
FDA approves Gavreto for RET-altered thyroid cancers
The FDA granted accelerated approval to pralsetinib for treatment of certain patients with RET-altered thyroid cancer.
FDA approves Gavreto for lung cancer subset
The FDA granted accelerated approval to pralsetinib for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer.
VIDEO: Precision medicine benefits patients with NSCLC
In this video, Vivek Subbiah, MD, associate professor at The University of Texas MD Anderson Cancer Center, highlighted a subgroup analysis from the LIBRETTO-001 trial that included patients with RET-fusion positive non-small cell lung cancer and CNS metastases.